Breaking News Instant updates and real-time market news.

NTRP

Neurotrope

$0.30

-0.0326 (-9.88%)

, LLY

Eli Lilly

09:35
11/23/16
11/23
09:35
11/23/16
09:35

Neurotrope President says 'deeply regrets' news on Eli Lilly's solanezumab

Neurotrope (NTRP) issued a statement on Eli Lilly's (LLY) experimental drug solanezumab. Lilly stated that, based upon results from its recent Phase 3 clinical trial, solanezumab failed to improve cognition of patients with mild Alzheimer's disease. Dr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer stated' "I deeply regret the news released today that Lilly's latest trial of its leading Alzheimer's drug candidate has failed. Lilly's dedication and persistence to finding a cure for this devastating affliction deserves everyone's admiration and gratitude. Repeated attempts to treat or even slow the relentless progression of Alzheimer's disease by targeting the red flag in patient's brains called amyloid plaques have continued to lead to such disappointing outcomes. Neurotrope has focused all of its resources on regenerative medicine that would replace the lost synaptic networks that are so consistently associated with the breakdown of human cognitive functions. Bryostatin, a drug that induces growth of new networks to replace those that have degenerated while also degrading plaques and tau tangles, may also address the red flags of this scourge threatening increasing numbers of the world's aging populations. At Neurotrope, we believe that treating Alzheimer's disease is a daunting challenge that will need to be treated by a drug with multi modal efficacy. We believe that our drug bryotstatin may be the drug. The top line results of our Phase 2 study with 148 patients is expected to be announced in April 2017. We hope, at that time, that a new therapy will be viewed as a possible future treatment for this disease."

NTRP

Neurotrope

$0.30

-0.0326 (-9.88%)

LLY

Eli Lilly

  • 04

    Dec

NTRP Neurotrope
$0.30

-0.0326 (-9.88%)

LLY Eli Lilly

11/23/16
JPMS
11/23/16
NO CHANGE
Target $85
JPMS
Overweight
JPMorgan sees 'attractive opportunity' amid Eli Lilly selloff
JPMorgan analyst Chris Schott lowered his price target for Eli Lilly to $85 from $95 after the phase III trial of solanezumab missed on both primary and secondary endpoints. Beyond solanezumab, Lilly has a diverse range of new product opportunities that support 5% sales and mid-teens earnings growth, Schott tells investors in a research note. With the shares down 13% to $65.81 in pre-market trading, the analyst sees an "attractive opportunity." He keeps an Overweight rating on Lilly.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $100
JEFF
Buy
Eli Lilly still expects to grow revenue, says Jefferies
Jefferies analyst Jeffrey Holford says that while the solanezumab Phase III trial failure is disappointing, Eli Lilly management expects to grow revenue between 2015 and 2020 while expanding margins. Further, the company is still pursuing the Alzheimer's indication though a number of other programs, Holford tells investors in a research note. The analyst previously estimated a negative solanezumab trial outcome could see the stock down $12. Shares of Lilly are currently down $10.19 to $65.80 in pre-market trading. Holford keeps a Buy rating on Lilly with a $100 price target.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Buy
Citi sees four reasons why Biogen Alzheimer's drug can still work
Citi analyst Robyn Karnauska sees four reasons why Biogen's (BIIB) Alzheimer's drug aducanumab can still work following the failure of Eli Lilly's (LLY) solanezumab. The analyst lists difference in mechanism of action, efficacy in an end-point-dependent manner, patient population and endpoints as why she thinks Biogen's drug can have a different outcome than Lilly's. The analyst has a Neutral rating on Biogen with a $305 price target.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $310
JEFF
Buy
Biogen selloff may be an overreaction, says Jefferies
Jefferies analyst Brian Abrahams believes selloff in shares of Biogen (BIIB) following Eli Lilly's (LLY) Alzheimer's failure may be an overreaction. Signals of activity seen for Lilly's sola "do maintain some possibility" that Biogen's aducanumab could "ultimately make it over the line," Abrahams tells investors in a research note. He keeps a Hold rating on Biogen with a $310 price target, however, viewing the risk/reward as balanced.

TODAY'S FREE FLY STORIES

QRVO

Qorvo

$66.19

-1.01 (-1.50%)

, SWKS

Skyworks

$94.70

-0.61 (-0.64%)

13:59
02/26/17
02/26
13:59
02/26/17
13:59
Periodicals
Qorvo, Skyworks look like better bets in mobile chips, Barron's says »

Qualcomm (QCOM) and…

QRVO

Qorvo

$66.19

-1.01 (-1.50%)

SWKS

Skyworks

$94.70

-0.61 (-0.64%)

QCOM

Qualcomm

$57.22

0.08 (0.14%)

INTC

Intel

$36.53

0.35 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

  • 19

    Mar

  • 04

    Apr

  • 05

    Apr

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

13:59
02/26/17
02/26
13:59
02/26/17
13:59
Conference/Events
J.C. Penney participates in a conference call with Aegis Capital »

Aegis Capital hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAM

Boston Beer

$159.20

1.3 (0.82%)

13:52
02/26/17
02/26
13:52
02/26/17
13:52
Periodicals
Boston Beer looks expensive, Barron's says »

Despite dropping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$29.38

-0.09 (-0.31%)

13:33
02/26/17
02/26
13:33
02/26/17
13:33
Periodicals
Axalta Coating could rise 20% or more, Barron's says »

Axalta Coating looks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPN

Global Payments

$78.97

0.76 (0.97%)

13:30
02/26/17
02/26
13:30
02/26/17
13:30
Periodicals
Global Payments could offer 15% upside, Barron's says »

Shares of Global Payments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

RIG

Transocean

$13.75

-0.56 (-3.91%)

13:07
02/26/17
02/26
13:07
02/26/17
13:07
Periodicals
Transocean could rally 35% or more over next several years, Barron's says »

"Patient"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TV

Grupo Televisa

$26.44

0.69 (2.68%)

12:57
02/26/17
02/26
12:57
02/26/17
12:57
Periodicals
Grupo Televisa could rise 20% or more in a year, Barron's says »

Grupo Televisa's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$56.56

-1.12 (-1.94%)

12:46
02/26/17
02/26
12:46
02/26/17
12:46
Periodicals
Harley-Davidson looks overvalued, Barron's says »

Harley-Davidson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIFE

aTyr Pharma

$3.38

-0.05 (-1.46%)

12:29
02/26/17
02/26
12:29
02/26/17
12:29
Hot Stocks
FDA grants Orphan designation for aTyr Pharma muscular dystrophy product »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGU

Agrium

$99.37

-1.19 (-1.18%)

, AAL

American Airlines

$46.28

0.18 (0.39%)

04:55
02/26/17
02/26
04:55
02/26/17
04:55
Conference/Events
BMO Capital to hold a conference »

26th Global Metals &…

AGU

Agrium

$99.37

-1.19 (-1.18%)

AAL

American Airlines

$46.28

0.18 (0.39%)

ABX

Barrick Gold

$19.54

-0.12 (-0.61%)

AEM

Agnico Eagle

$45.32

-0.06 (-0.13%)

ANTO

Use ANFGY

BLT

Blount

CCO

Clear Channel Outdoor

$4.65

0.1797 (4.02%)

FCX

Freeport McMoRan

$13.25

-0.23 (-1.71%)

FNV

Franco-Nevada

$65.89

-0.85 (-1.27%)

GEM

Pepsi-Gemex ADR

$29.39

-0.3 (-1.01%)

GG

Goldcorp

$16.57

-0.25 (-1.49%)

HBM

Hudbay Minerals

$8.00

0.25 (3.23%)

IVN

trades under IVPAF

NUE

Nucor

$60.86

-0.03 (-0.05%)

PDL

Project Design Labs

POT

Potash

$17.87

-0.2 (-1.11%)

RIO

Rio Tinto

$41.69

-0.82 (-1.93%)

SLW

Silver Wheaton

$21.15

-0.36 (-1.67%)

STLD

Steel Dynamics

$35.59

0.07 (0.20%)

TECK

Teck Resources

$20.72

-0.09 (-0.43%)

NEM

Newmont Mining

$36.08

0.22 (0.61%)

MOS

Mosaic

$31.42

-0.41 (-1.29%)

AA

Alcoa

$34.48

0.16 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 05

    Mar

  • 22

    Mar

  • 23

    Mar

  • 02

    May

AGU

Agrium

$99.37

-1.19 (-1.18%)

, AAL

American Airlines

$46.28

0.18 (0.39%)

16:10
02/25/17
02/25
16:10
02/25/17
16:10
Conference/Events
BMO Capital to hold a conference »

26th Global Metals &…

AGU

Agrium

$99.37

-1.19 (-1.18%)

AAL

American Airlines

$46.28

0.18 (0.39%)

ABX

Barrick Gold

$19.54

-0.12 (-0.61%)

AEM

Agnico Eagle

$45.32

-0.06 (-0.13%)

ANTO

Use ANFGY

BLT

Blount

CCO

Clear Channel Outdoor

$4.65

0.1797 (4.02%)

FCX

Freeport McMoRan

$13.25

-0.23 (-1.71%)

FNV

Franco-Nevada

$65.89

-0.85 (-1.27%)

GEM

Pepsi-Gemex ADR

$29.39

-0.3 (-1.01%)

GG

Goldcorp

$16.57

-0.25 (-1.49%)

HBM

Hudbay Minerals

$8.00

0.25 (3.23%)

IVN

trades under IVPAF

NUE

Nucor

$60.86

-0.03 (-0.05%)

PDL

Project Design Labs

POT

Potash

$17.87

-0.2 (-1.11%)

RIO

Rio Tinto

$41.69

-0.82 (-1.93%)

SLW

Silver Wheaton

$21.15

-0.36 (-1.67%)

STLD

Steel Dynamics

$35.59

0.07 (0.20%)

TECK

Teck Resources

$20.72

-0.09 (-0.43%)

NEM

Newmont Mining

$36.08

0.22 (0.61%)

MOS

Mosaic

$31.42

-0.41 (-1.29%)

AA

Alcoa

$34.48

0.16 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 05

    Mar

  • 22

    Mar

  • 23

    Mar

  • 02

    May

SO

Southern Company

$50.50

0.83 (1.67%)

15:07
02/25/17
02/25
15:07
02/25/17
15:07
Conference/Events
Southern Company participates in a conference call with Wolfe Research »

Wolfe Utilties Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 03

    Mar

DK

Delek US

$23.19

-0.21 (-0.90%)

15:04
02/25/17
02/25
15:04
02/25/17
15:04
Conference/Events
Delek US management participates in a dinner meeting with Wolfe Research »

Wolfe Gas & Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ANTM

Anthem

$163.83

-0.09 (-0.05%)

15:00
02/25/17
02/25
15:00
02/25/17
15:00
Conference/Events
Anthem management to meet with Wolfe Research »

Wolfe Healthcare Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MCO

Moody's

$113.29

0.06 (0.05%)

14:56
02/25/17
02/25
14:56
02/25/17
14:56
Conference/Events
Moody's analysts participate in a meeting with Wolfe Research »

Wolfe Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 05

    Mar

ONCS

OncoSec

$1.39

-0.03 (-2.11%)

, NKTR

Nektar

$13.45

0.25 (1.89%)

04:55
02/25/17
02/25
04:55
02/25/17
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2017 ASCO-SITC Clinical…

ONCS

OncoSec

$1.39

-0.03 (-2.11%)

NKTR

Nektar

$13.45

0.25 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MMM

3M

$187.41

0.22 (0.12%)

, BIOL

BIOLASE

$1.49

-0.01 (-0.67%)

04:55
02/25/17
02/25
04:55
02/25/17
04:55
Conference/Events
Chicago Dental Society to hold a meeting »

Chicago Dental Midwinter…

MMM

3M

$187.41

0.22 (0.12%)

BIOL

BIOLASE

$1.49

-0.01 (-0.67%)

COF

Capital One

$92.61

-0.8 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNECY

Renesas

$4.14

-0.17 (-3.94%)

, ISIL

Intersil

19:04
02/24/17
02/24
19:04
02/24/17
19:04
Hot Stocks
Renesas sees Intersil acquisition accretive to non-GAAP EPS, free cash flows »

Renesas Electronics…

RNECY

Renesas

$4.14

-0.17 (-3.94%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$173.53

1.61 (0.94%)

18:45
02/24/17
02/24
18:45
02/24/17
18:45
Conference/Events
Henry Schein management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

TWX

Time Warner

$97.28

0.6225 (0.64%)

18:38
02/24/17
02/24
18:38
02/24/17
18:38
Periodicals
Turner, Univision to win U.S. Champions League rights, Bloomberg reports »

Turner, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRUE

TrueCar

$14.28

0.18 (1.28%)

18:33
02/24/17
02/24
18:33
02/24/17
18:33
Hot Stocks
TrueCar's ALG sees February total new vehicle sales 1.325M units, down 1.4% »

ALG projects total new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

GE

General Electric

$30.19

0.17 (0.57%)

18:24
02/24/17
02/24
18:24
02/24/17
18:24
Hot Stocks
GE does not see after-tax charges from GE Capital exit plan to exceed $23B »

GE said in a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CE

Celanese

$88.79

-0.88 (-0.98%)

18:02
02/24/17
02/24
18:02
02/24/17
18:02
Hot Stocks
Celanese announces vinyl acetate-based emulsions price increases in Asia »

Celanese announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ELNK

EarthLink

$5.63

-0.22 (-3.76%)

, WIN

Windstream

$7.27

-0.02 (-0.27%)

17:56
02/24/17
02/24
17:56
02/24/17
17:56
Hot Stocks
EarthLink, Windstream holders approve merger »

EarthLink (ELNK)…

ELNK

EarthLink

$5.63

-0.22 (-3.76%)

WIN

Windstream

$7.27

-0.02 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

PFE

Pfizer

$34.26

0.2 (0.59%)

17:43
02/24/17
02/24
17:43
02/24/17
17:43
Periodicals
Pfizer subpoenaed in investigation of charity connections, Bloomberg says »

Pfizer has received two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 01

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.